Weekly Sepsis Research Analysis
This week’s sepsis literature highlights a blend of mechanistic discovery and high-quality clinical evidence. A mechanistic Nature Communications paper defines an RPSA–OLFM4 neutrophil migratory checkpoint with translational potential, while a large pragmatic NEJM randomized trial shows no kidney-outcome advantage of balanced crystalloids over 0.9% saline in pediatric septic shock despite biochemical differences. A Science Advances study identifies a conserved NFATc1-bound enhancer controlling B
Summary
This week’s sepsis literature highlights a blend of mechanistic discovery and high-quality clinical evidence. A mechanistic Nature Communications paper defines an RPSA–OLFM4 neutrophil migratory checkpoint with translational potential, while a large pragmatic NEJM randomized trial shows no kidney-outcome advantage of balanced crystalloids over 0.9% saline in pediatric septic shock despite biochemical differences. A Science Advances study identifies a conserved NFATc1-bound enhancer controlling B cell IL-10 that impacts survival in endotoxemia, pointing to a novel immunoregulatory axis. Together these works emphasize tractable host-directed targets, the continuing importance of rigorous fluid trials, and enhancer-level immune regulation as an actionable research direction.
Selected Articles
1. RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis.
This mechanistic study using myeloid-specific Rpsa knockout mice, patient neutrophils, adoptive transfer, and therapeutic modulation identifies an RPSA–OLFM4 checkpoint that sustains RhoA/ROCK1/pMLC2 signaling and MYH9 uropod localization to enable neutrophil migration. RPSA deficiency upregulated OLFM4, disrupted cytoskeletal polarity, impaired migration, and worsened infection outcomes; targeting the axis restored migration and improved survival in infected and septic mice. Human septic neutrophils showed the same RPSAlow/OLFM4high phenotype, supporting translational relevance.
Impact: Reveals a previously unrecognized, mechanistically deep migratory checkpoint with direct translational opportunities to restore neutrophil trafficking and host defense in sepsis.
Clinical Implications: Supports development of assays for RPSA/OLFM4 as biomarkers of neutrophil migratory competence and motivates early-phase trials of interventions that modulate this axis to enhance bacterial clearance in selected sepsis patients.
Key Findings
- Myeloid-specific Rpsa deletion reduced neutrophil infiltration and worsened Streptococcus suis serotype 2 infection in mice.
- RPSA deficiency induced OLFM4 overexpression, inhibited RhoA/ROCK1/pMLC2 signaling, reduced MYH9 and mislocalized it from uropods, disrupting migration.
- Septic patient neutrophils showed decreased RPSA and increased OLFM4 correlated with impaired migration.
- Therapeutic targeting of the RPSA–OLFM4 axis restored neutrophil migration and improved outcomes in infected and septic mice.
2. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
In a pragmatic, multinational randomized trial across 47 emergency departments (n≈8,482 analyzed), balanced crystalloids did not reduce the composite MAKE30 outcome (death, new renal replacement therapy, persistent kidney dysfunction) compared with 0.9% saline in children treated for suspected septic shock (3.4% vs 3.0%; no significant difference). Balanced fluids did reduce hyperchloremia and hypernatremia but produced similar hospital-free days and other safety outcomes, supporting equivalence for kidney-related outcomes and informing fluid choice by electrolyte and availability considerations.
Impact: A large, rigorously executed pragmatic RCT that directly informs front-line fluid selection in pediatric septic shock and clarifies that balanced crystalloids do not confer kidney-outcome benefit over saline.
Clinical Implications: Either balanced crystalloids or 0.9% saline are reasonable for resuscitation in pediatric septic shock; clinicians should individualize fluid choice based on electrolyte status, risk of hyperchloremia, and resource availability, while prioritizing timely antibiotics and hemodynamic support.
Key Findings
- No significant difference in MAKE30 between balanced crystalloids and 0.9% saline (3.4% vs 3.0%; RR 1.10; P=0.85).
- Balanced fluids reduced hyperchloremia (31.4% vs 49.0%) and hypernatremia (1.8% vs 3.1%) but had similar hospital-free days and safety outcomes.
- Large pragmatic design across 47 EDs with ITT analysis provides high external validity.
3. Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.
This mechanistic genomic study identifies a conserved noncoding enhancer (CNS-9 in mouse; CNS-12 in human) bound by NFATc1 that mediates chromatin looping to the IL-10 promoter and drives B cell IL-10 production, primarily from B1a cells. Deletion of CNS-9 or B cell–specific NFATc1 reduced IL-10, exacerbated inflammation, and decreased survival in LPS endotoxemia models, indicating a conserved regulatory axis that could be targeted to augment anti-inflammatory B cell responses in sepsis.
Impact: Defines a conserved enhancer-based regulatory mechanism for B cell IL-10 with in vivo survival effects, opening a new molecularly specific avenue for immunoregulatory therapies in sepsis.
Clinical Implications: Provides a rationale to develop strategies (pharmacologic, genetic, or epigenetic) to enhance B cell IL-10 production in hyperinflammatory sepsis; also suggests potential biomarkers of regulatory B cell function for patient stratification.
Key Findings
- CNS-9 is an NFATc1-bound enhancer that promotes chromatin looping to the IL-10 promoter in B cells.
- B1a cells are the predominant IL-10–producing B cells governed by this enhancer–NFATc1 axis.
- Deletion of CNS-9 or B cell–specific NFATc1 reduces IL-10, exacerbates inflammation, and decreases survival in LPS-induced sepsis models; human homolog CNS-12 shows similar function.